Curran, Dominic
Exelixis (United States)
2 papers on CoChatORCID 0000-0003-0256-3045
Most cited papers
- Verified
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Yau, T., Kaseb, A., Cheng, A.-L., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., et al. (2024) · The Lancet Gastroenterology & Hepatology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 97
- Verified
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
Neal, J. W., Santoro, A., Viteri, S., Ponce Aix, S., Fang, B., Lim, F. L., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., et al. (2022) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free